CRTX — CRISM Therapeutics Share News
0.000.00%
Last trade - 00:00- £8.12m
- £7.77m
- £0.03m
Crism Therapeutics: Phase 2 Clinical Trial Progress Update
Crism Therapeutics: Holding(s) in Company
Crism Therapeutics: Holding(s) in Company
Crism Therapeutics: Result of Retail Offer
Crism Therapeutics: Notice of General Meeting
Crism Therapeutics: Retail Offer to raise up to £100,000
Crism Therapeutics: Placing of £2.5 million
Crism Therapeutics: Positive Preclinical Data for Docetaxel ChemoSeed
Brief: CRISM Therapeutics Corporation Says Andrew Webb To Continue As Interim Executive Chair
Crism Therapeutics: Board Changes
Brief: Crism Therapeutics Provides Update On Phase 2 Clinical Trial Of Irinotecan-Chemoseed In Glioblastoma
Crism Therapeutics: Phase 2 Clinical Trial Progress Update
Crism Therapeutics: Result of Retail Offer
Crism Therapeutics: Holding(s) in Company
Brief: CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026
Crism Therapeutics: Half Year Report
Crism Therapeutics: Notice of Interim Results and IMC Presentation
Crism Therapeutics: Approval for phase 2 clinical trial
Crism Therapeutics: AGM Statement